Skip to main content
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. — Investor Relations & Filings

Ticker · CCCC ISIN · US12529R1077 US Manufacturing
Filings indexed 497 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country US United States of America
Listing US CCCC

About C4 Therapeutics, Inc.

https://c4therapeutics.com/

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of small-molecule medicines through targeted protein degradation (TPD). The company's proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform is utilized to create therapeutics that selectively destroy disease-causing proteins. C4 Therapeutics' primary focus is on developing treatments for cancer and other diseases. Its clinical pipeline includes investigational candidates such as cemsidomide (CFT7455) for hematologic malignancies, CFT8919 for solid tumors with specific genetic mutations, and CFT1946 for BRAF V600 mutant cancers.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-15 English
10-Q - C4 Therapeutics, Inc. (0001662579) (Filer)
Interim / Quarterly Report
2026-05-12 English
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
Regulatory Filings
2026-05-12 English
ARS - C4 Therapeutics, Inc. (0001662579) (Filer)
Annual Report
2026-04-29 English
DEF 14A - C4 Therapeutics, Inc. (0001662579) (Filer)
Proxy Solicitation & Information Statement
2026-04-29 English
8-K - C4 Therapeutics, Inc. (0001662579) (Filer)
Regulatory Filings
2026-04-10 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.